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Background: Carotid endarterectomy (CEA) has been shown to be effective in stroke prevention for patients with
symptomatic or asymptomatic carotid artery stenosis. Although several prospective randomized trials indicate that
carotid artery stenting (CAS) is an alternative but not superior treatment modality, there is still a significant lack of
long-term data comparing CAS with CEA. This study presents long-term results of a prospective, randomized,
single-center trial.
Methods: Between August 1999 and April 2002, 87 patients with a symptomatic high-grade internal carotid artery stenosis
(>70%)were randomized toCASorCEA.After amedian observation timeof 6614.2months (CAS) and6412.1months
(CEA), 42 patients in each groupwere re-evaluated retrospectively by clinical examination and documentation of neurologic
events. Duplex ultrasound imaging was performed in 61 patients (32 CAS, 29 CEA), and patients with restenosis >70%
were re-evaluated by angiography.
Results:During the observation period, 23 patients (25.2%) died (10 CAS, 13 CEA), and three were lost to follow up. The
incidence of strokes was higher after CAS, with four strokes in 42 CAS patients vs none in 42 CEA patients. One transient
ischemic attack occurred in each group. A significantly higher rate of restenosis >70% (6 of 32 vs 0 of 29) occurred after
CAS compared with CEA. Five of 32 CAS patients (15.6%) presented with high-grade (>70%) restenosis as an indication
for secondary intervention or surgical stent removal, and three presented with neurologic symptoms. No CEA patients
required reintervention (P < .05 vs CAS). A medium-grade (<70%) restenosis was detected in eight of 32 CAS patients
(25%) and in one of 29 CEA patients (3.4%). In five of 32 CAS (15.6%) and three of 29 CEA patients (10.3%), a
high-grade stenosis of the contralateral carotid artery was observed and treated during the observation period.
Conclusion: The long-term results of this prospective, randomized, single-center study revealed a high incidence of
relevant restenosis and neurologic symptoms after CAS. CEA seems to be superior to CAS concerning the development
of restenosis and significant prevention of stroke. However, the long-term results of the ongoing multicenter trials have
to be awaited for a final conclusion. (J Vasc Surg 2008;48:93-8.)Carotid endarterectomy (CEA) has been proven to be
effective in prevention of stroke in patients with symptom-
atic1,2 and asymptomatic3,4 carotid artery stenosis. In re-
cent years, carotid artery stenting (CAS) has emerged as an
alternative treatment modality. However, the short-term
results (periprocedural complication and 30-day follow-up)
of most recent prospective randomized multicenter studies
have not shown an advantage of CAS compared with
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sis. Therefore, CAS is only recommended and approved for
symptomatic high-risk patients7 or should be performed in
prospective, randomized studies. Nevertheless, CAS is
widely used both in asymptomatic and symptomatic pa-
tients and even in young patients.
Despite increasing evidence of restenosis after internal
carotid artery stenting, prospective data from randomized
trials on long-term restenosis and its risk for further stroke
are lacking. The aim of this study was to re-evaluate patients
of a prospective, randomized single center trial CAS vs CEA
performed between 1999 and 2002 in patients with severe
symptomatic carotid artery stenosis focusing on long-term
outcome such as stroke recurrence, restenosis, and death.
MATERIAL AND METHODS
Study design and patients. The protocol was ap-
proved by the ethics committee of the University of Re-
gensburg and was performed according to the Declaration
of Helsinki. The study was a prospective, randomized,
single-center trial comparing CAS vs CEA in patients with
70% symptomatic carotid artery stenosis as defined by
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Trial (NASCET) criteria from digital subtraction angiogra-
phy (DSA) with a 1-year follow-up. After written consent,
87 patients were randomized between August 1999 and
April 2002.
An experienced radiologist performed CAS using a
Carotid Wallstent (Boston Scientific, Natick, Mass), with-
out a protection device. All CEAs were done with the
eversion technique.8 To achieve comparability of the pro-
cedures, CAS and CEA were performed under local or
regional anesthesia. In all CAS and CEA patients, peripro-
cedural and postprocedural medical treatment included 75
mg of clopidogrel and 100 mg of aspirin daily for 1 month;
thereafter, all patients received 300 mg of aspirin daily. All
patients were monitored for 24 hours by electrocardiogram
and blood pressure measurements. If any abnormalities or
symptoms occurred, cardiac enzymes were obtained. The
study design and preliminary results from 23 patients have
been published elsewhere.9
Follow-up. Neurologic and clinical examinations
were performed by an independent neurologist at 6months
and 1 year after treatment in all patients. A duplex ultra-
sound (DUS) examination (Siemens Elegra, 2.5PL20,
7.5L40, Issaquah, Wash) was done after 3, 6, and 12
months, and cerebral magnetic resonance imaging (Mag-
netom Symphony, Siemens, Erlangen, Germany) and DSA
(Angiostar Plus, Siemens) was done after 1 year according
to the protocol.
The retrospective long-term follow-up with clinical,
neurologic, and DUS examinations (Sonoline Antares, Sie-
mens) were started in August 2006. The evaluation of
restenosis was performed by DUS imaging and quantified
as shown in Table I.10 However, detailed differentiation
between postprocedural DSA findings (remaining stenosis)
and newly developed restenosis was not performed. In case
of a restenosis70% of the treated carotid artery, DSA was
performed. Follow-up examinations were done by a staff
neurologist who was independent from the surgical/inter-
ventional trial staff. The degree of stenosis was determined
as stated in Table I and categorized as 50%, 50% to 70%,
and 70%. For patients who died, the medical records of
the attending physician and the last hospital records were
obtained.
Statistical analysis. All data are expressed as median
Table I. Duplex ultrasound criteria for the quantification
Criteria 0 1-30 30-50
Peak systolic velocity, m/s
(KHz Doppler) 1.2 1.25 (4) 1.25 (4
ICA/CCA index 0 0 1.8-2
End-diastolic velocity, m/s 1
Turbulences  () 
CCA, Common carotid artery; ICA, internal carotid artery.
aAccording to McCabe et al.10 All stenoses 70% were re-evaluated by dig
Endarterectomy Trial criteria.standard deviation or as absolute count and percentage oftotal. Kaplan-Meier analysis was followed by a log-rank test.
All statistical tests were performed using SPSS 13.0 soft-
ware (SPSS Inc, Chicago, Ill). Values of P  .05 were
considered statistically significant.
RESULTS
Between August 1999 and April 2002, 87 patients
were randomized and treated in the study (Table II).
Owing to the initialization of the almost identical Stent-
Protected Angioplasty Versus Carotid Endarterectomy
(SPACE) protocol,5 the randomization was stopped in
2002.
The 1-year results are presented in Table III. Although
the number of enrolled patients is quite small, the 1-year
results revealed a trend towards a higher neurologic com-
plication rate and asymptomatic ipsilateral cerebral lesions
on magnetic resonance after CAS. One stroke (neurologic
Table II. Baseline characteristics of patients
Variable All Stent group CEA group
Patients, No. 87 43 44
Age, mean  SD y 68.5  7.9 67.9  9.1 68.4  6.6
Age 70, No. 41 20 21
Risk factors
Hypertension 68 34 34
Current or past smoker 37 19 18
Coronary vascular
disease 38 18 20
Diabetes mellitus 34 19 15
Hypercholesterolemia 45 22 23
Peripheral vascular
disease 16 8 8
2 risk factors 45 23 22
Presenting symptoms
Stroke 30 12 16
TIA 41 23 18
Amaurosis fugax 21 8 13
Stenosis
Average degree,
mean  SD % 84.9  9.2 84.7  9.4 85.1  9.2
Contralateral ICA, 70% 8 2 6
Vertebral artery,
70%/occlusion 15 6 9
CEA, Carotid endarterectomy; ICA, internal carotid artery; SD, standard
deviation; TIA, transient ischemic attack.
stenosisa
Stenosis (%)
50-70 70-90 90 99 Pseudo-occlusion 100
2.5 (4-8) 5 (8-16) 5 (16)
2-4 4-8 8
1-1.4 1.4 1.5 Pseudo-venous flow
  
btraction angiography according to North American Symptomatic Carotidof re
) 
ital susymptoms 24 hours) was observed in the CAS group.
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after CAS and in two patients after CEA. A higher local
complication rate, mainly due to wound bleeding, was
observed after CEA. This was attributed to the high peri-
operative and postoperative platelet inhibition with clopi-
dogrel and aspirin as well as heparin medication, according
to the protocol. Two early restenosis 70% (4.8%) were
observed after CAS that required reintervention/surgery
1 year. No restenosis was detected 1 year after CEA.
The final follow-up of this study was performed after
66  14.2 months in CAS patients and 64  12.1 months
in CEA. During the observation period, 23 patients
(26.4%) died (10 CAS, 13 CEA, Table IV), which can be
attributed to themean age at treatment of 68.5 7.9 years.
The groups had similar overall survival (Fig 1). We were
unable to re-evaluate three patients (3.4%).
A significantly higher rate of ipsilateral strokes after
CAS (4 of 42) was observed compared with CEA (0 of 42;
Fig 2). One CAS patient died from a lethal ipsilateral stroke
3 years after treatment. Three patients sustained ipsilateral
stroke at 1.3, 1.7, and 2.2 years, respectively, after the
intervention. A TIA occurred in one CAS patient 6.3 years
after treatment due to a restenosis. One CEA patient, who
was receiving permanent oral anticoagulation due to an
Table III. Risk of stroke or death or other treatment-
related outcome 1 year after carotid artery stenting or
carotid endarterectomy
Outcome event CAS (n  43) CEA (n  44)
Nonfatal stroke 1 0
Transient ischemic attack 3 2
Death 0 0
Myocardial infarction 0 1
Hematoma 1 6
Infection 0 1
Cranial nerve injury 0 1
Restenosis 70% 2 0
CAS, Carotid artery stenting; CEA, carotid endarterectomy.
Table IV. Cause of deatha during the observation period
(median 65  13 months)
Cause of death CAS (n  10) CEA (n  13)
Ipsilateral stroke 1 0
Cardiac failure/MI 4 3
Malignancy 2 3
Liver failure 0 1
Lung embolism 0 1
Diabetic coma 1 0
GI ischemia/bleeding 1 1
Parkinson disease 0 1
Unknown 1 3
CAS, Carotid artery stenting; CEA, carotid endarterectomy; GI, gastroin-
testinal; MI, myocardial infarction.
aAccording to the medical records of the attending physician or the last
hospital records.absolute arrhythmia, presented with a TIA at 51 monthsafter treatment, but there was no evidence for a restenosis.
There was no difference between ipsilateral and overall
stroke rate (Fig 2, B).
Weobserved a significantly higher restenosis of70% and
occlusion rate after CAS compared with CEA (6 of 32 vs 0 of
29). The rate of restenosis of the treated ipsilateral carotid
artery is shown in Fig 3, A. Furthermore, a medium-grade
(70%) restenosis of the treated internal carotid artery was
detected in 8 of 32 CAS patients (25%) and in 1 of 29 CEA
patients (3.4%).
Two of the restenoses were diagnosed at 7 and 12
months after stent implantation, whereas the four other
restenoses/stent occlusions were detected, respectively, at
1.7, 2.2, 5.9, and 6.3 years after CAS. Two types of
restenosis were found. Three patients showed high-grade
stenosis due to kinking at the distal end of the stent, and
stent explantation with graft interposition was performed
because a reintervention with percutaneous transluminal
angioplasty (PTA) and a stent would not have resolved the
underlying cause for restenosis. In two patients, significant
intimal hyperplasia resulted in a high-grade in-stent reste-
nosis. No high-grade stenosis was detected in any of the
CEA patients, and only one patient after CEA had a reste-
nosis 50%.
The reintervention rate after CAS was significantly
increased compared with CEA (Fig 3, B). In five of 32
patients (15.6%) after CAS, reintervention with surgical
stent removal was necessary due to a high-grade (70%)
restenosis in four or acute stent occlusion in one. Three of
these patients had neurologic symptoms. One patient, who
had an ipsilateral stroke 1.3 years after CAS treatment,
presented with a medium-grade restenosis (50% to 70%)
but refused a further reintervention. One patient with stent
occlusion and stroke was not treated. No CEA patients
required reintervention.
Disease progression to a high-grade stenosis of the
Fig 1. Kaplan-Meier curves show overall survival for 42 patients
with carotid artery stenting (CAS) and 42 patients with carotid
endarterectomy (CEA).contralateral carotid artery was detected and treated in five
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(10.3%) during the observation period, which was not
statistically significant. This finding, however, further em-
phasizes the similarity between these two groups.
DISCUSSION
For the first time, to our knowledge, this study presents
long-term results of patients with symptomatic high-grade
internal carotid artery stenosis treated in a prospective,
randomized trial comparing CAS vs CEA. These data,
obtained after a median observation time 5 years, give
clear evidence that the value of CAS might be hampered by
a significantly higher rate of restenosis compared with CEA.
Two of the restenoses appeared1 year, whereas the other
Fig 2. A, Kaplan-Meier curves show freedom from ipsilateral
stroke (neurologic symptoms 24 hours) for 42 patients with
carotid artery stenting (CAS) and 42 patients with carotid endar-
terectomy (CEA). *P  .041 CEA vs CAS. B, Kaplan-Meier
curves show freedom from all neurologic events (stroke, transient
ischemic attack). P  .092 CEA vs CAS.progressed during 3 to 6 years after CAS.This long-term restenosis/occlusion rate (6 of 32) after
CAS observed in our study is high, but it is supported by
data of a retrospective analysis with a 21% restenosis rate
(50%) after 6 months in 171 patients, with 12.8% of the
patients requiring reintervention or surgery.11 A meta-
analysis of 34 studies surveying 4185 CAS patients revealed
a restenosis rate after 2 years of 7.5% for stenoses of 50% to
70% and 4% for stenosis70%. In contrast, a meta-analysis
summarizing five trials with 2465 CEA patients showed a
restenosis rate (50% stenosis) of 2.5% for eversion CEA
and 5.2% for conventional CEA. The observation time of
these studies was 1 to 3 years.12
These data indicate that restenosis rates after CAS might
be slightly higher than after CEA and higher than previously
suggested.13 This hypothesis is partly supported by results
from two prospective trials—6.3% vs 3.6% from Carotid
Fig 3. A, Kaplan-Meier curves show freedom from restenosis
(70%)/occlusion in 32 patients with carotid artery stenting
(CAS) and 29 patients with carotid endarterectomy (CEA). *P 
.023 CEA vs CAS. B, Kaplan-Meier curves show freedom from
reintervention in 42 CAS patients and 42 CEA patients. *P .027
CEA vs CAS.Revascularization using Endarterectomy or Stenting Sys-
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tebral Artery Transluminal Angioplasty Study (CAVATAS)—
comparing restenosis rates of CAS vs CEA.10,14 It has to be
mentioned, though, that none of the cited studies or our
own study differentiate between restenosis and remaining
stenosis after CAS. This is because stenting rarely achieves
close to 0% stenosis because the atherosclerotic obstruction
has not been removed.
Our study identified two main causes for the develop-
ment of restenosis. One is the compliance mismatch at the
end of the rigid stent in combination with an elongation of
vessels in elderly patients that leads to restenosis and kink-
ing at the distal end of the stent. The type of stent used may
influence this, and further studies should investigate this
type of complication for various types of stent, such as
closed-cell or open-cell design compared with the fairly
rigid and long carotid Wallstent that was used in this study.
This problem did not occur with CEA because pre-existing
elongation can be resolved, especially by using the eversion
technique. If restenosis occurs due to kinking, stent explan-
tation with graft interposition seems mandatory. Reinter-
ventions with PTA and stenting would not resolve the
underlying cause for restenosis and might aggravate the
problem or shift it distally.
Two patients presented with significant intimal hyper-
plasia that resulted in a high-grade, long-segment in-stent
restenosis or occlusion. Neointimal formation is a physio-
logic healing reaction of the vessel wall after angioplasty/
stenting or surgery.15 Whether the exclusive use of the
carotid wall stent may at least be partly causative for the
high restenosis rate cannot be excluded. Lin et al16 re-
ported a 10% restenosis rate (60%) after 4 years using the
same carotid Wallstent. However, all stents bear the theo-
retic disadvantage that the plaque material is not removed
during CAS as it is in CEA. This may lead to an application
of high radial expansion forces leading to a possible over-
dilatation of the vessel wall and increased risk of neointimal
hyperplasia.
Another important issue in this discussion is whether
restenosis after CAS is of clinical relevance leading to neu-
rologic symptoms. Lal et al17 reported no neurologic com-
plications due to a recurrent stenosis after CAS in a study
with 118 patients and a calculated, cumulative restenosis
rate (80%) of 6.4% after 5 years. Skelly et al18 described
no neurologic symptoms in 101 patients and a 11% reste-
nosis rate (60%) after a mean observation period of 6
months. The low rate of neurologic events in these studies
was attributed to the fact that stent restenosis does rarely
lead to turbulent flow, platelet activation by shear stress,
and most important, plaque rupture.
In contrast to these groups, however, we did observe
neurologic complications with clinical relevance. Although
the number of patients in our study was low, we observed a
high restenosis rate and a trend towards a higher rate of
neurologic events after CAS compared with CEA. We
therefore concluded that restenosis after CAS is correlated
with the incidence of neurologic symptoms. Supporting
this point of view are the data of Ricotta et al19 andAvramovic et al,20 who reported a significant incidence of
neurologic symptoms due to restenosis after CEA. This
leads to our conclusion that restenosis after CAS has to be
treated according to the same indications as primary carotid
artery stenosis. We recommend surgical stent explantation
in case of restenosis caused by kinking, in emergency situ-
ations, and if repeat PTAs are not advisable due to a
long-segment restenosis.
CONCLUSIONS
This is the first report, to our knowledge, on long-term
results from a prospective randomized trial comparing CAS
vs CEA in symptomatic carotid artery stenosis. Although
the significance of the results is limited owing to the rather
low number of patients studied, we observed a markedly
increased restenosis/occlusion rate after CAS compared
with CEA. These restenoses appeared 1 year as well as
during the long-term follow-up. Furthermore, this high
restenosis rate was associated with a higher incidence of
neurologic symptoms.
In synopsis with the short-term results of the SPACE and
the Endarterectomy Versus Angioplasty in Patients With
Symptomatic Severe Carotid Stenosis (EVA-3S) trials5,6 that
showed no superiority and not even equivalence of CAS to
CEA, we conclude that the widespread use of CAS is not
justified unless the long-term results of these studies allow
definite conclusions about the value of CAS in carotid
artery disease. Until then, CAS should be avoided in
younger patients and should be limited to randomized
trials and high-risk patients who are unfit for surgery.
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